About the author
Jeremy Swisher, MD
Nonsurgical sports medicine. About Dr. Swisher Official UCLA Health profile (opens in a new tab)
Start here
Three points worth knowing.
The product matters
A2M is a protein, not one standardized injection. Different processing methods can concentrate different proteins and cells.
Protection is not regrowth
Animal cartilage-protection findings do not establish human cartilage regeneration, lasting disease modification, or prevention of knee replacement.
Keep the whole plan
Exercise, activity planning, and weight management when relevant remain core knee-OA care. An emerging injection should not displace them.8
After a knee-OA diagnosis: start with the foundation exercise program or use the advanced progression when appropriate. Read the complete knee-OA care guide for the broader plan.
The rationale
What is an A2M knee injection?
Alpha-2-macroglobulin, or A2M, is naturally present in blood plasma. It can trap certain proteases, enzymes that break down proteins, and limit their access to larger targets. Laboratory studies show effects on enzymes involved in cartilage breakdown. That makes A2M a research target; it does not by itself establish treatment benefit.3
Some systems process a patient's blood to make an A2M-rich plasma fraction. This is not necessarily purified A2M. Other proteins may also be concentrated, and the contents depend on the preparation.
Related products have separate evidence.
PRP, autologous protein solution such as nSTRIDE, conditioned serum such as Orthokine, and recombinant A2M research drugs are different preparations. Their study results cannot simply be relabeled as evidence for an office-prepared A2M concentrate. A2M is a protein, not a stem cell.
The studies that matter
What do A2M knee injection studies show?
- 01
Thompson et al., 2024
Randomized human trial
Design: A single-center, double-blind trial enrolled 75 people with symptomatic Kellgren-Lawrence grade 2 or 3 knee OA, grades on an X-ray severity scale; 68 completed 12 weeks. It compared A2M-rich PRP concentrate, conventional PRP, and methylprednisolone, a corticosteroid.
Result: Several symptom scores improved within the A2M group, but score changes did not significantly differ among the three groups.
Practical meaning: The trial did not establish superiority or prove equivalence. Without a saline/placebo group, it cannot show how much improvement came from A2M itself rather than natural symptom changes or the injection context. Its small size and short follow-up also limit conclusions about durability.
- 02
Showel et al., 2025
Human blood-sample study
Design: Samples from 10 patients were used to test a plasma-filtration method.
Result: The method concentrated biologically active A2M along with other proteins. It did not test knee pain, function, or cartilage repair.
Practical meaning: Being able to make a concentrate is different from proving that injecting it improves a patient's knee.
- 03
Wang, 2014; Sun, 2024
Laboratory and animal studies
Design: Wang studied human tissue and cells plus a rat injury model; Sun used a minipig post-traumatic OA model.
Result: A2M reduced cartilage damage in the rat and minipig models. The human tissue and cell experiments helped investigate the proposed mechanism.
Practical meaning: These studies support further research. Human tissue experiments are not patient treatment trials, and induced animal injuries do not establish results in longstanding human OA.
Read Wang et al. (opens in a new tab) Read Sun et al. (opens in a new tab)
- 04
Mayo A2MRP pilot
ClinicalTrials.gov record
Design: A 20-person, open-label, single-group pilot studied A2M-rich plasma for symptomatic knee OA, with safety follow-up through one year.
Status: Completed; no results are posted as of October 2, 2026.
Practical meaning: A registered or completed study is not evidence that treatment works. A study without a comparison group also cannot establish superiority.
Earlier conference reports of the randomized cohort are not additional independent trials. A blood-preparation study, animal experiment, and trial registry should not be counted as three demonstrations of clinical benefit.
Before deciding
Ask for evidence that matches the product and your goal.
A2M's routine role remains uncertain. First confirm the pain source, OA severity, prior treatment response, and a meaningful functional goal. Consider the evidence and tradeoffs of other knee injection options alongside continued rehabilitation.
- 01
What exactly would be injected?
Ask about the processing system, final volume, measured A2M content when available, and what other proteins or cells are present.
- 02
Which human study supports this preparation?
Ask whether the cited research used the same product, diagnosis, and treatment schedule. Animal data and another orthobiologic's trial are not substitutes.
- 03
What improvement would justify the treatment?
Agree on pain and function measures, such as walking or stair tolerance, a reassessment plan, and alternatives if there is no worthwhile response.
- 04
What is the total cost?
Request a written estimate including preparation, injection, guidance, visits, and any proposed repeat treatment. Verify coverage with the clinic and health plan; consultation coverage does not establish procedure coverage.
Understand the FDA wording.
Clearance of blood-processing equipment is tied to that device and its intended use. It should not be confused with FDA approval of an A2M injection to treat osteoarthritis. Ask for the actual product name and regulatory record rather than relying on a general “FDA cleared” claim.710
Safety and aftercare
What are the risks of A2M knee injections?
Autologous means prepared from your own blood. Blood collection can cause bruising or lightheadedness. Joint injection can cause soreness, swelling, bleeding, or infection. The limited A2M evidence does not reliably quantify rare or long-term harms. Sterile technique and an appropriate diagnosis matter with every joint injection.6
Review bleeding risk, current medicines, infection, allergies, and planned surgery with the treating clinician. Do not stop prescribed blood thinners on your own. A universal A2M dose, repeat schedule, medication-holding rule, or recovery timetable has not been established; obtain individualized instructions and a rehabilitation plan.
Do not wait on a possible joint infection.
Seek same-day urgent assessment for a new hot, red, rapidly swelling knee, severe worsening pain, or inability to bear weight, with or without fever.9 Call 911 for trouble breathing, chest pain, fainting, or another medical emergency.
Common questions
A2M questions, answered directly.
Is A2M the same as PRP?
No. PRP concentrates platelets, while A2M-rich preparations aim to concentrate a plasma protein. A2M is naturally present in plasma and PRP, and some A2M preparations contain other proteins or cells. The exact product matters.
Is A2M better than PRP or cortisone?
That has not been established. The published randomized comparison did not find significantly better short-term outcomes with A2M. A small study finding no significant difference also does not prove the treatments are equivalent.
Does A2M regrow cartilage or prevent knee replacement?
Neither claim is established in people. Laboratory and animal studies support a cartilage-protection hypothesis, but they do not demonstrate durable cartilage regrowth or prevention of knee replacement after an A2M-rich plasma injection.
How long does relief last, and how many injections are needed?
A reliable duration of benefit and an optimal repeat schedule have not been established. Ask for the evidence supporting the exact preparation and proposed schedule, along with an individualized medication and rehabilitation plan.
Can knee studies be used to recommend A2M for my hip, shoulder, or tendon?
Not by themselves. Evidence from one joint, diagnosis, or preparation should not be generalized to another. The source of pain needs to be established, and the proposed treatment needs evidence relevant to that condition.
Does FDA clearance of the processing equipment mean the injection is FDA approved for arthritis?
No. Device clearance is tied to the device and its intended use. It should not be confused with FDA approval of an A2M injection to treat osteoarthritis. Ask for the exact product name, FDA record, and stated intended use.
Who has been studied for A2M knee injections?
The published randomized trial enrolled people with symptomatic Kellgren-Lawrence grades 2 or 3 knee osteoarthritis, grades on an X-ray severity scale. That does not establish an ideal candidate or justify the same treatment for severe arthritis, another joint, or another diagnosis.
What should I ask about A2M injection cost and insurance?
Do not assume coverage. Ask the treating clinic and your health plan to confirm the exact preparation, procedure, image guidance, and billing before treatment. Obtain a written estimate for the full proposed course. This page does not quote a price or establish coverage.
Evidence
Sources and further reading
Clinical studies, preparation research, preclinical work, and regulatory guidance are identified separately above.
How this evidence guide was assembled: PubMed, publisher records, and ClinicalTrials.gov were checked for human A2M knee-OA evidence, with selected foundational laboratory studies and official safety guidance. This is a focused educational review, not a systematic review. The published trial abstract supports the reported outcomes; its full report was not available for this review, so exact doses and adverse-event counts are not quoted.
- Thompson et al. The Effectiveness of Alpha-2-Macroglobulin Injections for Osteoarthritis of the Knee. Bulletin of the Hospital for Joint Diseases, 2024. PMID: 39259950. (opens in a new tab)
- Showel et al. Preparation of alpha-2 macroglobulin-rich plasma from human blood: technique and compositional analysis... Journal of Cartilage & Joint Preservation, 2025. DOI: 10.1016/j.jcjp.2025.100255. (opens in a new tab)
- Wang et al. Identification of alpha-2-macroglobulin as a master inhibitor of cartilage-degrading factors that attenuates the progression of posttraumatic osteoarthritis. Arthritis & Rheumatology, 2014. PMID: 24578232. (opens in a new tab)
- Sun et al. Alpha-2-Macroglobulin Attenuates Posttraumatic Osteoarthritis Cartilage Damage by Inhibiting Inflammatory Pathways With Modified Intra-articular Drilling in a Yucatan Minipig Model. American Journal of Sports Medicine, 2024. PMID: 39214071. (opens in a new tab)
- Mayo Clinic. Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP), Safety and Efficacy in Symptomatic Moderate Knee Osteoarthritis: A Pilot Study. ClinicalTrials.gov: NCT06329492. (opens in a new tab)
- Uson et al. EULAR recommendations for intra-articular therapies. Annals of the Rheumatic Diseases, 2021. PMID: 34035002. (opens in a new tab)
- FDA. Premarket Notification 510(k): device clearance and intended use. (opens in a new tab)
- NICE. Osteoarthritis in over 16s: diagnosis and management, NG226. Core treatment recommendations. (opens in a new tab)
- NHS. Septic arthritis: symptoms and urgent assessment. Reviewed September 3, 2026. (opens in a new tab)
- FDA. Is It Really 'FDA Approved'? Approval, clearance, and registration explained. (opens in a new tab)
Published and evidence checked October 2, 2026. New results may change the interpretation. This educational page does not establish which product is appropriate, available, or covered for a particular patient.